How Target Therapy can Induce Cardiotoxicity: The Onco-Cardiologist Point of View
DOI:
https://doi.org/10.17140/CSMMOJ-3-119Abstract
The life expectancy of an oncological patient has been increased significantly decades due to the evolution of cancer therapies. The aim of this paper is to review how these new target molecules, which have a direct impact on the cancer cell as opposed to the classical chemotherapy, known to all of us for a long time. How do they act specifically? What are their cardiotoxic effects at a short and long time period? How can they be monitored? How can they be prevented and treated? And above all, how can we prevent an oncological patient to become a cardiovascular one later on, due to induced cardiotoxicity caused by oncological therapies. We have to treat our patients as a whole and not only, target therapy to one of the pieces of the puzzle.
References
Lenneman CG, Sawyer DB. Cardio-oncology an update on cardiotoxicity of cancer-related treatment. Circ Res. 2016; 118: 1008-1020. doi: 10.1161/CIRCRESAHA.115.303633
Hahn VS, Lenihan L, Ky B. Cancer therapy–induced cardio-toxicity: Basic mechanisms and potential cardioprotective thera-pies virginia shalkey. J Am Heart Assoc. 2014; 3(2): e000665. doi: 10.1161/JAHA.113.000665
Zamorano JL, Lancellotti P, Muñoz DR, et al. 2016 ESC Posi-tion Paper on cancer treatments and cardiovascular toxicity de-veloped under the auspices of the ESC Committee for Practice Guidelines The Task Force for cancer treatments and cardiovas-cular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016; 37: 2768-2801. doi: 10.1093/eurheartj/ehw211
Cardinale D, Colombo A, Lamantia G, et al. Anthracycline-induced cardiomyopathy: Clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol. 2010; 55(3): 213- 220. doi: 10.1016/j.jacc.2009.03.095
Cardinale D, Colombo A, Sandri MT, et al. Prevention of high-dose chemotherapy–induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Cir-culation. 2006; 114: 2474-2481. doi: 10.1161/CIRCULA-TIONAHA.106.635144
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Cancer Studies and Molecular Medicine (CSMM) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.
